EZH2 and EED inhibitors have been discovered and demonstrated clinical efficacy in lymphoma patients.[10] EZH2 inhibitors directly target the catalytic subunit, while EED inhibitors bind to EED in the H3K27me3 pocket and inhibit PRC2 allosterically. Here, EZH2 is linked to lymphoma.